“Multinational companies’ clinical studies bring KRW 52 billion domestic medical expense reduction effect”

It was researched multinational clinical studies which have been conducted by global pharmaceutical companies has made medical expense reduction worth of, at least, KRW 52 billion in the domestic market.

According to the ‘2015 KRPIA Annual Report’ published by the Korean Research-based Pharma Industry Association, the number of domestic patients who participated in Phase 1 to 4 clinical studie...